AMC Entertainment (AMC)
(Delayed Data from NYSE)
$5.05 USD
+0.02 (0.40%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $5.04 -0.01 (-0.20%) 7:58 PM ET
2-Buy of 5 2
C Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
AMC 5.05 +0.02(0.40%)
Will AMC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for AMC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AMC
Here's Why You Should Retain Red Rock Resorts (RRR) Stock Now
JAKKS Pacific (JAKK) Stock Plunges 48% in 6M: Hold or Fold?
AMC: What are Zacks experts saying now?
Zacks Private Portfolio Services
GameStop (GME) Down 13% in a Month: How to Play the Meme Stock?
Cooling Inflation Raises Rate Cut Hopes: 4 Solid Stocks to Buy
Xponential Fitness (XPOF) to Expand BFT Line-up in Scandinavia
Other News for AMC
IN BRIEF: Crism flags contract talks, reacts to share price surge
Does ‘I Like the Stock’ Mean ‘I Should Buy It’? Not Necessarily.
Cineworld leaning towards British restructuring, Sky News reports
Arizona Metals Corp Concludes Key Meeting
Meme Stock or Vaccine Stock? Novavax’s Identity Crisis and Why It Matters for Investors